From GlobeNewswire:

4D Molecular Therapeutics, Inc. announced it priced an upsized underwritten public offering of 6,586,015 shares of its common stock at a public offering price of $29.50 per share. It has also granted the underwriters a 30-day option to purchase up to an additional 1,525,423 shares of common stock at the public offering price. Goldman Sachs & Co. LLC, BofA Securities, Jefferies and Barclays are acting as joint book-running managers for the offering. The gross proceeds from the offering are expected to be approximately $300 million. The offering is expected to close on February 9, 2024, subject to customary closing conditions.

4D Molecular Therapeutics, Inc. is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. They’re advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases in ophthalmology, pulmonology, and cardiology.



Read more: 4D Molecular Therapeutics Announces Pricing of Upsized